HeartForce is proud to announce that it has successfully completed the entire data collection process in Uzbekistan consisting of:
(1) patients with high levels of coronary artery disease (Stenosis of ≥ 50% in at least one coronary artery),
(2) a healthy and age-matched control group and
(3) patients with mild to medium levels of occlusion to form a more homogeneous (balanced) database.
All collected data will be included in our final report that will be released in early April of 2023. The report will include an in-depth, evidence-based analysis for the determination of the overall CAD accuracy, sensitivity, and specificity of our screening technology. A scientific publication will follow in summer of 2023.